Journal of Clinical Medicine,
Journal Year:
2022,
Volume and Issue:
11(4), P. 955 - 955
Published: Feb. 12, 2022
Pituitary
tumors
(PT)
represent
in,
the
majority
of
cases,
benign
for
which
surgical
treatment
still
remains,
except
prolactin-secreting
PT,
first-line
therapeutic
option.
Nonetheless,
role
played
by
medical
therapies
management
such
tumors,
before
or
after
surgery,
has
evolved
considerably,
due
in
part
to
recent
development
well-tolerated
and
highly
efficient
molecules.
In
this
review,
our
aim
was
present
a
state-of-the-art
current
used
field
PT
benefits
caveats
each
them,
further
specify
their
positioning
algorithm
phenotype.
Finally,
we
discuss
future
therapies,
based
on
most
studies
published
field.
Journal of Neuroendocrinology,
Journal Year:
2023,
Volume and Issue:
35(4)
Published: March 25, 2023
Somatotropinomas
are
pituitary
tumors
with
a
heterogenous
clinical
behavior.
The
tumor
microenvironment
regulates
the
interaction
between
cells
and
host
immune
system,
potentially
modulating
Here,
we
aimed
to
investigate
infiltration
in
cohort
of
medically
naïve
acromegaly
patients.
A
retrospective,
monocenter
study
was
designed
analyze
presence
CD3+,
CD20+,
CD138+,
CD4+,
CD8+,
CD68+
samples
somatotropinomas
their
prognostic
significance
on
behavior
response
first
generation
somatostatin
analogs
(fg-SSA).
Thirty-six
patients
(23
females)
were
included
study.
Macroadenomas
identified
23
cases:
12
cavernous
sinus
invasion.
number
CD8+
lymphocytes
positively
correlated
CD4+
(p
=
.05,
r:0.245)
macrophages
.01,
r
0.291).
CD8+/CD4+
ratio
inversely
CD68+/CD8+
<
.001,
-0.626).
size
(maximum
diameter
p
.003,
0.574;
volume
.009,
0.566)
more
numerous
Ki-67
>
3%
(median
65/HPF,
IQR:15),
compared
cases
Ki67
50/HPF,
IQR:22,
.001).
CD138+
responsive
fg-SSA
(respectively
median
18/HPF
IQR:18
8/HPF
IQR:
6.5)
as
nonresponsive
14.5/HPF
IQR:40
.03;
3.5/HPF
14
.03).
act
single
predictor
fg-SSA,
independently
from
age,
GH
IGF-I
levels,
dimension
Our
results
support
that
generate
an
network
characteristic
infiltrate
may
predict
treatment
outcome.
International Journal of Molecular Sciences,
Journal Year:
2022,
Volume and Issue:
23(9), P. 4861 - 4861
Published: April 27, 2022
Corticotroph
cells
give
rise
to
aggressive
and
rare
pituitary
neoplasms
comprising
ACTH-producing
adenomas
resulting
in
Cushing
disease
(CD),
clinically
silent
ACTH
(SCA),
Crooke
cell
(CCA)
carcinomas
(CA).
The
molecular
pathogenesis
of
these
tumors
is
still
poorly
understood.
To
better
understand
the
genomic
landscape
all
lesions
corticotroph
lineage,
we
sequenced
whole
exome
three
SCA,
one
CCA,
four
ACTH-secreting
PA
causing
CD,
corticotrophinoma
occurring
a
CD
patient
who
developed
Nelson
syndrome
after
adrenalectomy
with
an
CA.
CA
was
lesion
highest
number
single
nucleotide
variants
(SNV)
genes
such
as
USP8,
TP53,
AURKA,
EGFR,
HSD3B1
CDKN1A.
USP8
variant
found
only
ACTH-CA
syndrome.
In
SNV
CDKN1A
were
present.
SNVs
present
whereas
two
AURKA
EGFR
found.
None
analyzed
showed
USP48,
BRAF,
BRG1
or
CABLES1.
amplification
17q12
tumors,
except
for
carcinoma.
functioning
shared
10q11.22
more
copy-number
variation
(CNV)
gains
single-nucleotide
variations
than
nonfunctioning
tumors.
Cancers,
Journal Year:
2022,
Volume and Issue:
14(17), P. 4093 - 4093
Published: Aug. 24, 2022
Background:
Aggressive
and
metastatic
PitNETs
are
challenging
conditions.
Immune
checkpoint
inhibitors
(ICIs)
currently
considered
in
cases
resistant
to
temozolomide
(TMZ).
However,
clinical
experience
is
essentially
limited
case
reports,
with
variable
outcomes.
Material
Methods:
The
effects
of
ICIs
on
12
aggressive/metastatic
from
the
literature
were
reviewed
analyzed
according
tumor
characteristics,
additional
description
a
silent-Pit1
responding
pembrolizumab.
Results:
Most
(10/13:
6
corticotroph,
3
lactotroph,
1
silent
Pit1);
aggressive
(2
lactotroph).
ICIS
was
used
either
as
monotherapy
or
combination.
At
last
follow-up
ICI,
complete
response
(CR)
present
partial
(PR)
2
(4/5
metastatic).
One
sustained
stable
disease
(SD)
reported.
Progressive
(PD)
observed
7
cases,
them
after
initial
SD
(n
=
1)
PR
3),
reported
deaths.
PDL1
expression
studied
10
high
(>95%)
Pit1-derived
(1
CR
remarkable
PR)
but
absent/low
(<1%)
remaining
(including
CP
PR).
Elevated
mutation
burden
could
be
informative
corticotroph
PitNETs,
especially
mismatch
repair-deficient
tumors.
Conclusion:
Significant
benefits
documented
about
half
TMZ-resistant
PitNETS.
High
associated
responses
may
dispensable.
Based
their
acceptable
tolerance
awaiting
recognized
predictors
response,
valuable
option
for
such
patients.
Journal of Clinical Medicine,
Journal Year:
2022,
Volume and Issue:
11(4), P. 955 - 955
Published: Feb. 12, 2022
Pituitary
tumors
(PT)
represent
in,
the
majority
of
cases,
benign
for
which
surgical
treatment
still
remains,
except
prolactin-secreting
PT,
first-line
therapeutic
option.
Nonetheless,
role
played
by
medical
therapies
management
such
tumors,
before
or
after
surgery,
has
evolved
considerably,
due
in
part
to
recent
development
well-tolerated
and
highly
efficient
molecules.
In
this
review,
our
aim
was
present
a
state-of-the-art
current
used
field
PT
benefits
caveats
each
them,
further
specify
their
positioning
algorithm
phenotype.
Finally,
we
discuss
future
therapies,
based
on
most
studies
published
field.
